CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$4.50−0.17 (-3.64%)
Close on Nov 18, 2026Market cap $350.75MP/E –Yield –
CorMedix operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CorMedix's operating income for the twelve months ending Jun 30, 2026 was $217.04M, up 340.1% year over year. For fiscal 2025 it was $150.14M. The highest annual figure on record is $150.14M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.14M | – |
| FY2024 | Dec 31, 2024 | -$22.36M | – |
| FY2023 | Dec 31, 2023 | -$48.96M | – |
| FY2022 | Dec 31, 2022 | -$30.62M | – |
| FY2021 | Dec 31, 2021 | -$29.44M | – |
| FY2020 | Dec 31, 2020 | -$27.22M | – |
| FY2019 | Dec 31, 2019 | -$21.01M | – |
| FY2018 | Dec 31, 2018 | -$26.86M | – |
| FY2017 | Dec 31, 2017 | -$32.92M | – |
| FY2016 | Dec 31, 2016 | -$24.76M | – |
| FY2015 | Dec 31, 2015 | -$16.65M | – |
| FY2014 | Dec 31, 2014 | -$8.90M | – |
| FY2013 | Dec 31, 2013 | -$4.92M | – |
| FY2012 | Dec 31, 2012 | -$3.00M | – |
| FY2011 | Dec 31, 2011 | -$7.21M | – |
| FY2010 | Dec 31, 2010 | -$8.51M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $42.91M | +119.6% |
| Q1 FY2026 | Mar 31, 2026 | $63.66M | +216.3% |
| Q4 FY2025 | Dec 31, 2025 | $59.13M | +357.1% |
| Q3 FY2025 | Sep 30, 2025 | $51.35M | – |
| Q2 FY2025 | Jun 30, 2025 | $19.54M | – |
| Q1 FY2025 | Mar 31, 2025 | $20.13M | – |
| Q4 FY2024 | Dec 31, 2024 | $12.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.70M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.92M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.38M | -351.4% |
| Q3 FY2019 | Sep 30, 2019 | -$5.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.54M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.92M | – |
| Q4 FY2018 | Dec 31, 2018 | $2.14M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.57M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.19M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.27M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.01M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.02M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.62M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.43K | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.16M | – |
See a number that looks wrong?